Role of in vitro release models in formulation development and quality control of parenteral depots

Expert Opinion on Drug Delivery

Volumn 6, Issue 12, 2009, Pages 1283-1295

  Larsen, Claus ^a   Larsen, Susan Weng ^a   Jensen, Henrik ^a   Yaghmur, Anan ^a   Østergaard, Jesper ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Convection and diffusion controlled mass transfer; Drug release mechanism; In vitro in vivo correlation; In vitro release model; Injection site; Parenteral depot

Indexed keywords

ISOPHANE INSULIN; LIPOSOME; MEDROXYPROGESTERONE ACETATE; METHYLPREDNISOLONE ACETATE; MICROSPHERE; PARENTERAL SOLUTION;

DRUG FORMULATION; DRUG RELEASE; HUMAN; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NANOPHARMACEUTICS; NONHUMAN; QUALITY CONTROL; REVIEW; SUSPENSION; SUSTAINED RELEASE FORMULATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, INTRA-ARTICULAR; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; QUALITY CONTROL;

EID: 71249151006     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903307431     Document Type: Review

References (127)

1. Larsen C, Stergaard J, Larsen SW, et al. Intra-articular depot formulation principles: Role in the management of postoperative pain and arthritic disorders. J Pharm Sci 2008;97:4622-4654 . A comprehensive review of the subject.
2. Berkland C, Pollauf E, Raman C, et al. Macromolecule release from monodisperse PLG microspheres: Control of release rates and investigation of release mechanism. J Pharm Sci 2007;96:1176-1191
3. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals: Workshop report. AAPS PharmSci 2002;4:E7
4. Burgess DJ, Crommelin DJ, Hussain AS, Chen ML. Assuring quality and performance of sustained and controlled released parenterals. Eur J Pharm Sci 2004;21:679-690
5. Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo considerations associated with parenteral sustained release products: A review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 2008;129:79-87
6. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/ special dosage forms. AAPS PharmSciTech 2003;4:E7
7. Uppoor VRS. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 2001;72:127-132
8. Woo BH, Kostanski JW, Gebrekidan S, et al. Preparation, characterization and in vivo evaluation of 120-day poly (D,L-lactide) leuprolide microspheres. J Control Release 2001;75:307-315
9. Young D, Farrell C, Shepard, T. In vitro/in vivo correlation for modified release injectable drug delivery systems. In: Burgess DJ, editor. Injectable dispersed systems. Formulation, processing, and performance. New York: Taylor & Francis Group, 2005. p. 159-176
10. Stevens LE, Missel PJ, Weiner AL. Controlled flow-through dissolution methodology: A high-performance system. Pharm Dev Technol 2008;13:135-153
11. Saarinen-Savolainen P, Jarvinen T, Taipale H, Urtti A. Method for evaluating drug release from liposomes in sink conditions. Int J Pharm 1997;159:27-33
12. Diaz RV, Llabres M, Evora C. One-month sustained release microspheres of I-125-bovine calcitonin - In vitro in vivo studies. J Control Release 1999;59:55-62
13. Washington C. Drug release from microdisperse systems - a critical-review. Int J Pharm 1990;58:1-12 . One of the first papers discussing the influence of sink condition on drug release characteristics.
14. D'Souza SS, Deluca PP. Methods to assess in vitro drug release from injectable polymeric particulate systems. Pharm Res 2006;23:460-74 . Contains an assessment of different release models used in the characterisation of microspheres.
15. Pedersen BT, Stergaard J, Larsen SW, Larsen C. Characterization of the rotating dialysis cell as an in vitro model potentially useful for simulation of the pharmacokinetic fate of intra-articularly administered drugs. Eur J Pharm Sci 2005;25:73-79
16. The dissolution procedure: Development and validation. Pharmacopeial Forum 2005;31:1463
17. Tingstad JE, Riegelman S. Dissolution rate studies I. Design and evaluation of a continuous flow apparatus. J Pharm Sci 1970;59:692-696 . Provision of a rationale for using sink conditions during dissolution testing of oral dosage forms.
18. Nicklasson M, Lindberg J, Borga B, et al. A collaborative study of the in vitro dissolution of phenacetin crystals comparing the flow through method with the USP Paddle method. Int J Pharm 1991;69:255-264
19. Shah AC, Nelson KG. Evaluation of a convective diffusion drug dissolution rate model. J Pharm Sci 1975;64:1518-1520 . Pioneering work on the subject.
20. Nelson KG, Shah AC. Convective diffusion-model for a transport-controlled dissolution rate process. J Pharm Sci 1975;64:610-614 . Pioneering work on the subject.
21. Stay MS, Xu J, Randolph TW, Barocas VH. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm Res 2003;20:96-102 . Simulation of the drug fate after depot administration.
22. Caldwell JR. Intra-articular corticosteroids - Guide to selection and indications for use. Drugs 1996;52:507-514
23. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs - Place in therapy. Drugs 1994;47:741-773
24. Chien YM. Long-acting parenteral drug formulations. J Parenter Sci Technol 1981;35:106-139 . Early comprehensive review on the subject.
25. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique 2. Diabetologia 2005;48:1988-1995
26. Porter CJH, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000;89:297-310
27. Levick JR. Microvascular architecture and exchange in synovial joints. Microcirculation 1995;2:217-233
28. Poli A, Scott D, Bertin K, et al. Influence of actin cytoskeleton on intra-articular and interstitial fluid pressures in synovial joints. Microvasc Res 2001;62:293-305
29. Simkin PA, Nilson KL. Trans-synovial exchange of large and small molecules. Clin Rheum Dis 1981;7:99-129
30. Simkin PA, Benedict RS. Iodide and albumin kinetics in normal canine wrists and knees. Arthritis Rheum 1990;33:73-79
31. Weinberger A, Simkin PA. Plasma proteins in synovial fluids of normal human joints. Semin Arthritis Rheum 1989;19:66-76
32. Owen SG, Francis HW, Roberts MS. Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br J Clin Pharmacol 1994;38:349-355
33. Simkin PA, Wu MP, Foster DM. Articular pharmacokinetics of protein-bound antirheumatic agents. Clin Pharmacokinet 1993;25:342-350
34. Medlicott NJ, Waldron NA, Foster TP. Sustained release veterinary parenteral products. Adv Drug Deliv Rev 2004;56:1345-1365 . Comprehensive treatise of the subject.
35. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993;73:1-78
36. Zuidema J, Kadir F, Titulaer HAC, Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm 1994;105:189-207
37. Ballard BE. Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J Pharm Sci 1968;57:357-378
38. Huang Y, Hubbard JW, Midha KK. The role of the lymphatic system in the presystemic absorption of fluphenazine after intramuscular administration of fluphenazine decanoate in rats. Eur J Pharm Sci 1995;3:15-20
39. Luo JP, Hubbard JW, Midha KK. The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: Ex vivo experiments in rats. Pharm Res 1998;15:1485-1489
40. Fredholt K, Larsen DH, Larsen C. Modification of in vitro drug release rate from oily parenteral depots using a formulation approach. Eur J Pharm Sci 2000;11:231-237
41. Larsen DB, Fredholt K, Larsen C. Addition of hydrogen bond donating excipients to oil solution: Effect on in vitro drug release rate and viscosity. Eur J Pharm Sci 2001;13:403-410
42. Larsen SW, Thomsen AE, Rinvar E, et al. Effect of drug lipophilicity on in vitro release rate from oil vehicles using nicotinic acid esters as model prodrug derivatives. Int J Pharm 2001;216:83-93
43. Minto CF, Howe C, Wishart S, et al. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: Effects of ester, injection site and injection volume. J Pharmacol Exp Ther 1997;281:93-102
44. Tanaka T, Kobayash H, Okumura K, et al. Biopharmaceutical studies on parenteral preparation - intramuscular absorption of drugs from oily solutions in rat. Chem Pharm Bull 1974;22:1275-1284
45. Larsen SW, stergaard J, Friberg-Johansen H, et al. In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration. Eur J Pharm Sci 2006;29:348-354
46. Larsen SW, Frost AB, stergaard J, et al. On the mechanism of drug release from oil suspensions in vitro using local anesthetics as model drug compounds. Eur J Pharm Sci 2008;34:37-44
47. Larsen DB, Joergensen S, Olsen NV, et al. In vivo release of bupivacaine from subcutaneously administered oily solution. Comparison with in vitro release. J Control Release 2002;81:145-154
48. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-1272
49. Yaghmur A, Glatter O. Characterization and potential applications of nanostructured aqueous dispersions. Adv Colloid Interface Sci 2009;147-48:333-342
50. Metselaar JM, Storm G. Liposomes in the treatment of inflammatory disorders. Expert Opin Drug Deliv 2005;2:465-476 . Comprehensive treatise of the potential utilities of liposomes.
51. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-160
52. Dingle JT, Gordon JL, Hazleman BL, et al. Novel treatment for joint inflammation. Nature 1978;271:372-373
53. Mantripragada S. A lipid based depot (DepoFoam- technology) for sustained release drug delivery. Prog Lipid Res 2002;41:392-406
54. Fong WK, Hanley T, Boyd BJ. Stimuli responsive liquid crystals provide 'on-demand' drug delivery in vitro and in vivo. J Control Release 2009;135:218-226
55. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000;10:305-309 (Pubitemid 30317466)
56. Heiati H, Tawashi R, Shivers RR, Phillips NC. Solid lipid nanoparticles as drug carriers 1. Incorporation and retention of the lipophilic prodrug 3¢-azido-3¢-deoxythymidine palmitate. Int J Pharm 1997;146:123-131
57. Heng D, Cutler DJ, Chan HK, et al. What is a suitable dissolution method for drug nanoparticles? Pharm Res 2008;25:1696-1701
58. Levy MY, Benita S. Drug release from submicronized o/w emulsion - a new in vitro kinetic evaluation model. Int J Pharm 1990;66:29-37
59. Bonacucina G, Cespi M, Misici-Falzi M, Palmieri GF. Colloidal Soft Matter as Drug Delivery System. J Pharm Sci 2009;98:1-42
60. Hitzman CJ, Wiedmann TS, Dai HQ, Elmquist WF. Measurement of drug release from microcarriers by microdialysis. J Pharm Sci 2005;94:1456-1466
61. Anderson M, Omri A. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv 2004;11:33-39
62. Drummond DC, Noble CO, Hayes ME, et al. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008;97:4696-4740 . Overview providing details about the in vivo fate of liposomes.
63. Jain JP, Modi S, Domb AJ, Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005;103:541-563
64. Heller J, Barr J, Ng SY, et al. Poly(ortho esters): Synthesis, characterization, properties and uses. Adv Drug Deliv Rev 2002;54:1015-1039
65. Sinha VR, Bansal K, Kaushik R, et al. Poly-epsilon-caprolactone microspheres and nanospheres: An overview. Int J Pharm 2004;278:1-23
66. Patil GV. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res 2003;58:219-247
67. Kumar MNVR, Muzzarelli RAA, Muzzarelli C, et al. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004;104:6017-6084
68. Shi Y, Li LC. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2005;2:1039-1058
69. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/ evaporation: Reviewing the state of the art of microsphere preparation process technology. J Control Release 2005;102:313-332 . Comprehensive treatise of the subject.
70. Jiang WL, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005;57:391-410
71. Berchane NS, Carson KH, Rice-Ficht AC, Andrews MJ. Effect of mean diameter and polydispersity of PLG microspheres on drug release: Experiment and theory. Int J Pharm 2007;337:118-126
72. Vert M, Schwach G, Engel R, Coudane J. Something new in the field of PLA/GA bioresorbable polymers? J Control Release 1998;53:85-92
73. Klose D, Siepmann F, Elkhamz K, Siepmann J. PLGA-based drug delivery systems: Importance of the type of drug and device geometry. Int J Pharm 2008;354:95-103
74. Faisant N, Siepmann J, Benoit JP. PLGA-based microparticles: Elucidation of mechanisms and a new, simple mathematical model quantifying drug release. Eur J Pharm Sci 2002;15:355-366 (Pubitemid 34436923)
75. Siepmann J, Faisant N, Akiki J, et al. Effect of the size of biodegradable microparticles on drug release: Experiment and theory. J Control Release 2004;96:123-134
76. Faisant N, Akiki J, Siepmann F, et al. Effects of the type of release medium on drug release from PLGA-based microparticles: Experiment and theory. Int J Pharm 2006;314:189-197
77. Zolnik BS, Burgess DJ. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 2008;127:137-145
78. Klose D, Azaroual N, Siepmann F, et al. Towards more realistic in vitro release measurement techniques for biodegradable microparticles. Pharm Res 2009;26:691-699
79. Liu FI, Kuo JH, Sung KC, Hu OY. Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: In vitro characterization and in vivo pharmacokinetic studies. Int J Pharm 2003;257:23-31
80. van Dijkhuizen-Radersma R, Wright SJ, Taylor LM, et al. In vitro/in vivo correlation for C-14-methylated lysozyme release from poly(ether-ester) microspheres. Pharm Res 2004;21:484-491
81. Zhang PC, Chen LL, Gu WW, et al. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 2007;28:1882-1888
82. Nash RA. Suspensions. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. Second ed. Basel: Marcel Dekker, 2002. p. 2654-2667
83. Akers MJ, Fites AL, Robinson RL. Formulation design and development of parenteral suspensions. J Parenter Sci Technol 1987;41:88-96
84. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: An overview. Eur J Pharm Biopharm 2004;58:445-455 . Comprehensive treatise of the subject.
85. Rothen-Weinhold A, Gurny R, Dahn M. Formulation and technology aspects of controlled drug delivery in animals. Pharm Sci Technol Today 2000;3:222-231
86. Yu LX, Foster TP, Sarver RW, Moseley WM. Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog. J Pharm Sci 1996;85:396-401
87. Madan PL. Sustained-release drug delivery systems: Part V, parenteral products. Pharm Manuf 1985;2:51-57
88. Crommelin DJ. In vitro release studies on drugs suspended in non-polar media II. The release of paracetamol and chloramphenicol from suspensions in liquid paraffin. Int J Pharm 1980;6:29-42
89. Crommelin DJ. In vitro release studies on drugs suspended in non-polar media I. The release of sodium chloride from suspensions in liquid paraffin. Int J Pharm 1980;5:305-316
90. Stout PJ, Howard SA, Mauger JW. Dissolution of pharmaceutical suspensions. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, 1991. p. 169-192
91. Larsen SW, stergaard E, Poulsen SV, et al. Diflunisal salts of bupivacaine, lidocaine and morphine - Use of the common ion effect for prolonging the release of bupivacaine from mixed salt suspensions in an in vitro dialysis model. Eur J Pharm Sci 2007;31:172-179
92. Gietz U, Arvinte T, Mader E, et al. Sustained release of injectable zinc-recombinant hirudin suspensions: Development and validation of in vitro release model. Eur J Pharm Biopharm 1998;45:259-264
93. Sartor O. Eligard: Leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61:25-31
94. Gehrke SH. Synthesis and properties of hydrogels used for drug delivery. In: Amidon GL, Lee PI, Topp EM, editors. Transport processes in pharmaceutical systems. New York: Marcel Dekker, Inc., 2000. p. 473-546
95. Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm 2008;355:1-18
96. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 2002;80:9-28 . One of first major reviews in the field.
97. Zentner GM, Rathi R, Shih c, et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 2001;72:203-215
98. Chen S, Singh J. Controlled release of growth hormone from thermosensitive triblock copolymer systems: In vitro and in vivo evaluation. Int J Pharm 2008;352:58-65
99. McHugh AJ. The role of polymer membrane formation in sustained release drug delivery systems. J Control Release 2005;109:211-221 . Detailed description of in situ polymer precipitation.
100. Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release 1999;62:333-344
101. Choi S, Baudys M, Kim SW. Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats. Pharm Res 2004;21:827-831
102. Hyun H, Kim YH, Song IB, et al. In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier. Biomacromolecules 2007;8:1093-1100
103. Katakam M, Ravis WR, Banga AK. Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J Control Release 1997;49:21-26 (Pubitemid 27417897)
104. Haglund BO, Joshi R, Himmelstein KJ. An in situ gelling system for parenteral delivery. J Control Release 1996;41:229-235
105. Wang Y, Lapitsky Y, Kang CE, Shoichet MS. Accelerated release of a sparingly soluble drug from an injectible hyaluronan-methylcellulose hydrogel. J Control Release 2009; doi:10.1016/j.jconrel.2009.05.025
106. Singh S, Singh J. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: In vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm 2007;328: 42-48
107. Kempe S, Metz H, Mäder K. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process. J Control Release 2008;130:220-235 . Comparison of the in vitro and in vivo in situ formulation process by use of EPR.
108. Graham PD, Brodbeck KJ, McHugh AJ. Phase inversion of PLGA solutions related to drug delivery. J Control Release 1999;58:233-245
109. Kranz H, Bodmeier R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int J Pharm 2007;332:107-114
110. Plourde F, Motulsky A, Couffin-Hoarau A-L, et al. First report on the efficacy of L-alanine-based in situ forming implants for the long-term parenteral delivery of drugs. J Control Release 2005;108:433-441
111. Vintiloiu A, Lafleur M, Bastiat G, Leroux J-C. In situ-forming oleogel implant for rivastigmine delivery. Pharm Res 2008;25:845-852
112. Okumu FW, Dao LN, Fielder PJ, et al. Sustained delivery of human ghrowth hormone from a novel gel system: SABERTM. Biomaterials 2002;23:4353-4358
113. Iyer SS, Barr WH, Karnes HT. Profiling in vitro drug release from subcutaneous implants: A review of current status and potential implications on drug product development. Biopharm Drug Dispos 2006;27:157-170 . Significant contribution to the area of in vitro release model development.
114. Iyer SS, Barr WH, Dance ME, et al. A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant. Int J Pharm 2007;340:104-118
115. James KC, Nicholls PJ, Roberts M. Biological half-lives of [4-14C]testosterone and some of its esters after injection into rat. J Pharm Pharmacol 1969;21:24-27
116. Hirano K, Ichihashi T, Yamada H. Studies on the absorption of practically water-insoluble drugs following injection V: Subcutaneous absorption in rats from solutions in water immiscible oils. J Pharm Sci 1982;71:495-500 (Pubitemid 12063720)
117. Larsen SW, Rinvar E, Svendsen O, et al. Determination of the disappearance rate of iodine-125 labelled oils from the injection site after intramuscular and subcutaneous administration to pigs. Int J Pharm 2001;230:67-75
118. Schultz K, Mollgaard B, Fisher AN, et al. Intramuscular rate of disappearance of oily vehicles in rabbits investigated by gamma-scintigraphy. Int J Pharm 1998;169:121-126
119. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24 . A comprehensive treatise of host responses to microsphere injection.
120. Anderson JM. In-Vivo Biocompatibility of Implantable Delivery Systems and Biomaterials. Eur J Pharm Biopharm 1994;40:1-8
121. Swartz MA, Fleury ME. Interstitial flow and its effects in soft tissues. Annu Rev Biomed Eng 2007;9:229-256 . An excellent treatise of solute transfer in the interstitium.
122. Hwang CW, Wu D, Edelman ER. Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Intervent 2003;5:7-12
123. D'Souza SS, Deluca PP. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech 2005;6
124. Kostanski JW, Deluca PP. A novel in vitro release technique for peptide containing biodegradable microspheres. AAPS PharmSciTech 2000;1:E4
125. Kim TK, Burgess DJ. Pharmacokinetic characterization C-14-vascular endothelial growth factor controlled release microspheres using a rat model. J Pharm Pharmacol 2002;54:897-905
126. Iyer SS, Barr WH, Karnes HT. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant. Int J Pharm 2007;340:119-125
127. Schliecker G, Schmidt C, Fuchs S, et al. In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J Control Release 2004;94:25-37